Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Cancer
- Disease
- Therapeutic
- Pharmaceuticals
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 237244
Licensed Compound shall mean Atiprimod (a/k/a Azaspiranes) and any analogs or derivatives described in the Patent Rights.
The license includes patents for Immunomodulatory Azaspiranes, and, Cytokine Inhibitors.
Atiprimod is an orally bio-available small molecule drug that displays multiple mechanisms of action. The drug has been shown to be antiangiogenic, inhibit secretion of VEGF and IL-6, elicit an apoptotic response (programmed cellular death), and inhibit phosphorylation of key kinases involved in tumor progression and survival including Akt and STAT3. The drug is presently in two clinical trials a Phase II trial in advanced carcinoid cancer patients, and a Phase I/IIa human clinical trial in relapsed or refractory multiple myeloma patients.
IPSCIO Record ID: 328195
The Licensed Compound shall mean Atiprimod (a/k/a Azaspiranes) and any analogs or derivatives described in the Patent Rights.
The Final Product shall mean any pharmaceutical composition approved for sale as a drug in a country in the Territory by the appropriate agency or governmental body in dosage form that contains a Licensed Compound and that is packaged and labeled for sale to the ultimate customer for use in the Licensed Field.
The patents include Immunomodulatory Azaspiranes, Cytokine Inhibitors, 2-[2-(Dimethylamino )ethyl]-8,8-dipropyl-2-azaspiro[ 4,5]decane dimaleate, N,N-dimethyl-B,B-dipropyl-2-azasprio [ 4,5]decane-2-propanamine dimalcare, N,N-diethyl-8,8-dipropyl-2-azaspiro [ 4,5] decane-2-propanamine, Immunomodulatory azaspiranes, and, Psoriasis treatment using Azaspiranes and a method of immunosuppression, using Azaspiranes in combination with cyclosporine).
Atiprimod's specific ability to lower the level of key growth factors, known to play an important role in the pathogenesis of multiple myeloma, is the basis for its potential use as a drug to treat this disease.
Licensee is a biopharmaceutical company focused primarily on the development of drugs to treat neuroendocrine cancer (including advanced carcinoid cancer), acute leukemia and gastrointestinal disorders and diseases.
IPSCIO Record ID: 6676
During fiscal year 2006, the Licensor received a licensing payment from the Licensee for Atiprimod.
IPSCIO Record ID: 369402
University grants an exclusive option to negotiate a worldwide, exclusive license to any Improvements made within two years of the effective date.
This agreement includes non-exclusive grant back to Licensor by Licensee.
Novel Mechanistically Altered Tyrphostins with Potent Antitumor Activity, and,
Compounds for Treatment of Cell Proliferative Diseases.
Licensee is a biopharmaceutical company focused on the development of drugs to treat relapsed (re-occurrence of active disease) or refractory acute leukemia, multiple myeloma (an incurable blood cancer that invades and proliferates in bone marrow), and advanced carcinoid cancer patients.
IPSCIO Record ID: 237253
Licensor grants an exclusive worldwide license under the Licensor Technology, with no right to sublicense, to the extent useful to permit Licensee to use Biomarkers to monitor the effectiveness of the Compound in the Field, including in human subjects, solely in connection with research and/or development of Drug Products. Licensor agrees that it shall negotiate in good faith with Licensee to reach agreement on a license to diagnostic products incorporating such Biomarkers for use solely in connection with the administration of the Drug Product in the Field. Licensor reserves all rights to Biomarkers and the use thereof for all purposes outside the Field.
This agreement also includes a non-exclusive grant back to Licensor.
The Compound shall mean VX-944 and and any of its hydrates, salts, stereoisomers, polymorphs, prodrugs or metabolites.
IMPDH shall mean Inosine 5 -monophosphate dehydrogenase.
Drug Product shall mean any pharmaceutical preparation in finished dosage form containing the Compound for administration to human patients for any and all uses in the Field.
VX-944 is a small molecule, selective, uncompetitive novel inhibitor directed against human IMPDH enzyme. IMPDH inhibitors have been demonstrated to induce growth arrest, and extensively investigated as immunosuppressants. Here we show that VX-944 inhibits growth of human multiple myeloma (MM) cell lines, including those resistant to conventional agents, via induction of apoptosis and S phase arrest in vitro.
IPSCIO Record ID: 263778
Licensor grants a co-exclusive license under the Licensors Licensed Know-How to clinically develop, make, have made, use, sell, offer for sale and import Co-Developed Products in the U.S.
Licensor grants a co-exclusive license under the Licensors Licensed Patents to clinically develop, make, have made, use, sell, offer for sale and import Co-Developed Products in the U.S.
Licensor grants an exclusive, subject to Licensors right to conduct Licensor Clinical Trials and work under the Backup Programs pursuant to this Agreement, license under the Licensor Licensed Know-How to clinically develop, make, have made, use, sell, offer for sale and import Royalty-Bearing Products in the U.S.; and Products in the Royalty Territory.
Licensor grants an exclusive, subject to Licensors right to conduct Licensor Clinical Trials and work under the Backup Programs pursuant to this Agreement, license under the Licensor Licensed Patents to clinically develop, make, have made, use, sell, offer for sale and import Royalty-Bearing Products in the U.S.; and Products in the Royalty Territory.
Licensor will grant a non-exclusive license to use such Licensor Marks solely in connection with the Commercialization of the Products in the Territory, the Trademark License Agreement.
Product means any therapeutic or prophylactic product that contains or comprises a Collaboration Compound. The Collaboration Compounds means XL184; and XL281.
XL184 means the small molecule compound with Licensor identifier 02977184; the small molecule compounds listed in the Letter Agreement; any Program Backups to 02977184; and any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, ester, or prodrug of the compound.
XL281 means the small molecule compound with Licensor identifier 03832819; the small molecule compounds listed in the Letter Agreement; any Program Backups to 03832819; and any isomer, racemate, salt, solvate, hydrate, metabolite, conjugate, ester, or prodrug of the compound.
XL184 provides a novel approach to the treatment of a variety of solid tumors where signaling through MET, VEGFR2 or RET plays an important role in dysregulated tumor growth and progression. XL184 has recently begun a Phase III clinical trials in medullary thyroid cancer, a disease in which RET mutations are found in a large proportion of patients. In addition, clinical trials to exploit the MET and VEGFR2 targeting of XL 184 are ongoing in patients with non-small cell lung cancer and glioblastoma. Preclinically, XL184 also exhibits inhibitory activity for .MET and VEGFR2 in a variety of breast, colon and brain tumor models.
XL28 l is a novel small molecule designed to selectively inhibit RAF kinase, which lies immediately downstream of RAS and is a key component of the RAS/RAF/MEK/ERK kinase signaling pathway. The RAS/RAF/MEK/ERK pathway plays a key role in the transmission of growth-promoting signals downstream of receptor tyrosine kinases. Dysregulation of this pathway plays a pivotal role in the progression of many human tumors, and inhibition of the pathway may be useful in the treatment of cancer. Phase I trials with this molecule are underway in order to select a dose and schedule for Phase II disease-directed trials.
